Resveratrol

Disclaimer: The information presented in this section is for educational and informational purposes only. It is not intended as medical advice. No supplement discussed on this site has been proven to prevent, stop, or reverse neurodegenerative disease. While some supplements have been studied for their potential to support aspects of cellular function, any observed effects are generally modest, variable between individuals, and highly context-dependent. Before starting any supplement, consult with a qualified healthcare professional. Appropriate professionals may include a physician, neurologist, pharmacist, nurse practitioner, physician assistant, or registered dietitian. This does not refer to wellness influencers, supplement sellers, health coaches, or practitioners without medical training in pharmacology, neurology, and drug-supplement interactions. Supplements may interact with medications or produce unintended side effects. The inclusion of any supplement on this site does not constitute a recommendation for use. Descriptions of mechanisms or research findings are provided to improve understanding of current scientific investigation, not to guide individual treatment decisions.

Overview

Resveratrol is a polyphenol found in foods such as grapes and red wine and is widely marketed for anti-aging effects. In neurodegeneration, it is commonly claimed to support cognition, reduce neuroinflammation, and influence Alzheimer-related pathology.

Resveratrol is plausible mechanistically, but still clinically inconclusive. It has attracted sustained interest because it intersects with pathways like inflammation, oxidative stress, and SIRT1-related signaling, but it has not become a validated treatment for major neurodegenerative disease.

Proposed Mechanisms

Resveratrol has been proposed to act through sirtuin inhibition. Sirtuins are enzymes that perform a myriad of functions, regulating gene expression, metabolism, and inflammation. They also consume NAD+ to function. This broad mechanism profile is part of why it remains so popular in the neurodegeneration literature.

Preclinical work, including in vivo studies, often reports improvement in pathology or behavioral readouts in Alzheimer-type models. The challenge has not been lack of biologic interest. The challenge has been demonstrating that these effects translate into reliable cognitive or disease-modifying benefit in patients.

Evidence Summary

Preclinical: The preclinical case is reasonably strong. Recent reviews continue to describe favorable in vivo data for resveratrol in models of Alzheimer’s and broader neurodegeneration, particularly around inflammation, oxidative stress, and amyloid-related pathways.

Translational / RCT / observational: Human evidence is mixed. A 2025 study reported that resveratrol improved certain CSF markers of neurodegeneration and inflammation in Alzheimer’s disease, suggesting biologic activity in patients. But this is not the same as proving meaningful clinical benefit, and reviews still describe the cognitive and disease-modifying evidence as limited or inconclusive. However, a phase II clinical trial of resveratrol was stopped because of the adverse effects it was having on the kidneys.

Evidence level

Low.

Resveratrol is more than pure hype because there is real biologic activity and some translational signal, but it still falls well short of being an evidence-backed neurodegenerative disease treatment.

Limitations

A major limitation is the persistent gap between mechanistic enthusiasm and clinical outcomes. Biomarker shifts can be interesting without translating into meaningful improvement in memory, function, or disease trajectory.

Another limitation is bioavailability and formulation variability. As with several polyphenol supplements, resveratrol’s extremely limited uptake in humans is one of the major limiting factors for it.

Finally there are safety concerns following the terminated clinical trial.

Safety and Considerations

Resveratrol is generally well tolerated in studied doses, but GI effects and supplement-quality variability matter. High doses have been associated with kidney problems.

Sources

Popat R, Plesner T, Davies F, Cook G, Cook M, Elliott P, Jacobson E, Gumbleton T, Oakervee H, Cavenagh J. “A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma
Turner RS et al. “A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.” Neurology. 2015.